BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated
to therapies and supportive care for cancer and AIDS patients, today announced its scientific
communications at upcoming international conferences on infectious diseases and oncology:
Loramyc®, indicated for fungal infections in immune-compromised patients with HIV
The 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
May 29 to June 2, 2009 – Orlando, Florida, USA.
Abstract: “Prevalence and management of oropharyngeal candidiasis (OPC) by medical and
radiation oncologists in cancer patients”.
At the American Conference for the Treatment of HIV (ACTHIV) that took place on May 15-
17, 2009 in Denver, Colorado, USA, BioAlliance Pharma presented the poster: “Once-Daily
Miconazole Mucoadhesive Buccal Tablet is an Effective and Safe Treatment for
Amep™, a biotherapy for Metastatic Melanoma treatment
American Society of Gene Therapy (ASGT) 12th Annual Meeting
May 27-30, 2009 – San Diego, California, USA
Poster: “Complete Melanoma Regressions after Electrotransfer of the p-AMEP™ Plasmid
Coding for an Anti-Angiogenic and Anti-Metastatic Peptide”, May 28.
Anti-integrases: new antiretroviral drugs for the treatment of resistant HIV-1
XVIII International HIV Drug Resistance Workshop
June 9-13, 2009 – Fort Myers, Florida, USA
Oral communication and poster: “New integrase binding inhibitors acting in synergy with
Raltegravir”, June 12.
Irinotecan SRN oral formulation for the treatment of advanced colorectal cancer
2nd Pharmaceutical Sciences Fair and Exhibition (PharmSciFair)
June 8-12, 2009, Nice, France
Oral communication: “Sustained Release Nanoparticles (SRN) for oral administration of
Irinotecan”, June 10.